BioVaxys Licensee SpayVac-for-Wildlife, Inc., Reports Further Positive Single-Dose Efficacy Data for Its Immunocontraceptive Vaccine and Initiation of Regulatory Submission Process

Executive Summary

• BioVaxys‑licensed SpayVac™ vaccine achieved a single‑dose fertility reduction to 11 % in free‑ranging red deer (vs. 86 % in controls) in a year‑long field study in Germany’s Bavarian Forest National Park.
• The study validates SpayVac’s efficacy across three deer species (red, fallow, white‑tailed), supporting broad commercial potential for wildlife population control.
• SpayVac‑for‑Wildlife has initiated regulatory submission to obtain approval for use in feral horses and free‑ranging deer, targeting a sizable royalty stream from future vaccine sales.

Key Details

• Study Design: 47 free‑ranging red deer monitored with camera traps, GPS collars, and fecal progesterone metabolites over one year.
• Efficacy Result: Fertility in vaccinated deer = 11 %; control group fertility = 86 %.
• Species Coverage: Clinical validation now includes fallow deer (Dama dama), white‑tailed deer (Odocoileus virginianus), and red deer (Cervus elaphus).
• Mechanism: Liposome‑based delivery platform licensed from BioVaxys; liposomes composed of naturally occurring phospholipids encapsulating the antigen.
• Regulatory Action: SpayVac‑for‑Wildlife has begun the submission process for regulatory approval of SpayVac, its first product targeting feral horses and free‑ranging deer populations.
• Commercial Outlook: CEO Kenneth Kovan (BioVaxys) projects a “healthy royalty stream” from vaccine sales given tens of millions of deer worldwide.
• Market Need: Overabundant deer cause agricultural damage, increase tick‑borne disease risk, vehicle collisions, and ecological impacts; non‑lethal control methods are in high demand where hunting is limited.
• Future Development: Ongoing trials for feral horses, farmed trout, Asian elephants, and other species; SpayVac CEO Tom D’Orazio emphasizes replication of efficacy across multiple animal models.

Notable Quotes

“SpayVac is further clinical demonstration of the single‑dose, long‑duration efficacy provided by our vaccine technology platform… we anticipate a healthy royalty stream from SpayVac vaccine sales.” – Kenneth Kovan, President & COO, BioVaxys

“It can have a meaningful impact in efforts to manage overabundant deer populations.” – Dr. Mark Fraker, VP of Operations, SpayVac‑for‑Wildlife

“These results are another example of replication and proof of concept that SpayVac pZP vaccine is very effective.” – Tom D’Orazio, CEO, SpayVac‑for‑Wildlife